Friday, 2 June 2017

Market Report Focused on Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2017

Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2017 is a new market research publication announced by Reportstack. This report provides an overview of the Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline landscape.
Type 1 diabetes (T1D) is an autoimmune disease in which a pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body’s immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. Risk factors of type 1 diabetes include genetics and family history, diseases of the pancreas and infection or illness. The signs and symptoms of type 1 diabetes include increased thirst and frequent urination, extreme hunger, weight loss, fatigue, irritability or unusual behavior.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 9, 32, 26, 2, 113, 34 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 2, 32 and 5 molecules, respectively.
Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Adocia AiCuris GmbH & Co KG Alteogen Inc Amarantus Bioscience Holdings Inc Amarna Therapeutics BV AntriaBio Inc apceth Biopharma GmbH Aphios Corp Araim Pharmaceuticals Inc Argos Therapeutics Inc Astellas Pharma Inc AstraZeneca Plc Athersys Inc Atlantic Bio Sci LLC Axxam SpA Beta-Cell NV Biocon Ltd BioLineRx Ltd BioLingus AG Biozeus BirchBioMed Inc Boehringer Ingelheim GmbH Caladrius Biosciences Inc Cancer Prevention Pharmaceuticals Inc Compugen Ltd ConjuChem LLC Daewoong Pharmaceutical Co Ltd Dance Biopharm Inc Denceptor Therapeutics Ltd Diabetology (Products) Ltd DiaMedica Therapeutics Inc Diamyd Medical AB Diasome Pharmaceuticals Inc DiaVacs Inc Dompe Farmaceutici SpA Eli Lilly and Company Ensol Biosciences Inc EpiVax Inc Escape Therapeutics Inc Evotec AG Fate Therapeutics Inc Generex Biotechnology Corp GeNeuro SA Geropharm LLC Gilead Sciences Inc GlaxoSmithKline Plc Grifols SA Hanmi Pharmaceuticals Co Ltd Heptares Therapeutics Ltd ImmusanT Inc Innopharmax Inc Intrexon Corp Ixchel Pharma LLC Johnson & Johnson Kadimastem Ltd Kamada Ltd Kasiak Research Pvt Ltd KPI Therapeutics Inc Lexicon Pharmaceuticals Inc Ligand Pharmaceuticals Inc Lonestar Heart Inc MacroGenics Inc Medestea Research & Production SpA MedImmune LLC Medtronic Plc Medy-Tox Inc Melior Discovery Inc Merck & Co Inc Meridigen Biotech Co Ltd Mitsubishi Tanabe Pharma Corp Neovacs SA Novo Nordisk A/S Noxxon Pharma AG Oramed Pharmaceuticals Inc Orgenesis Inc OSE Immunotherapeutics Paras Biopharmaceuticals Finland Oy Parvus Therapeutics Inc Pathfinder Cell Therapy Inc Pfizer Inc PharmaCyte Biotech Inc PharmaIN Corp Prometheon Pharma LLC Purzer Pharmaceutical Co Ltd RedHill Biopharma Ltd REGiMMUNE Corp Sanofi Selecta Biosciences Inc Semma Therapeutics Inc Sevion Therapeutics Inc Sotio AS Tetragenetics Inc Thermalin Diabetes LLC Toleranzia AB Transgene Biotek Ltd Traverse Biosciences Inc UCB SA Unicyte AG United Therapeutics Corp ViaCyte Inc XL-protein GmbH XOMA Corp Zealand Pharma AS Zensun (Shanghai) Sci & Tech Co Ltd
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research


Post a Comment

Subscribe to Post Comments [Atom]

<< Home